Terbinafine
Product Images NDC 71335-1668

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Terbinafine (NDC 71335-1668). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351668)

This appears to be information regarding medication packaging and storage. The medication being referenced is Lamisil 250mg Tablet made by InvaGen Pharmaceuticals Inc, with a package size of 30 tablets expiring on a certain date. The text includes instructions for storage and a warning to keep all drugs out of reach of children. The initial line mentions packaging by Bryant Ranch Prepach Bunbank.*

FDA Label Image

Image 2 (Terbinafine Str)

FDA Label Image

Image 1 (Terbinafine Table)

This is a report on adverse events recorded for individuals who were taking either Terbinafine or Placebo tablets. The data shows the percentage of people who experienced different types of symptoms and conditions while taking either Terbinafine or Placebo tablets. Some of the symptoms reported are headache, gastrointestinal issues such as diarrhea, dyspepsia, abdominal pain, nausea, flatulence, dermatological issues such as rash, pruritus, and urticaria, liver enzyme abnormalities, taste disturbance, and visual disturbance. The report shows the percentage of people who discontinued taking the medication due to the adverse events.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.